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Background/Aims: Chronic liquid and/or food stasis caused by retention esophagitis (RE) in achalasia is a notable endoscopic finding 
because of the presence of a thickened or whitish esophageal mucosa and histologically altered squamous hyperplasia. We aimed to 
identify the clinical features of RE associated with achalasia and to clarify the clinical definition of RE in achalasia as a precancerous 
lesion identified by analyzing biomarker expressions.
Methods: From 2006 to 2015, we retrospectively reviewed 37 patients with achalasia without previous treatment. Among them, 21 
patients had diagnostic findings of RE (RE+) and 16 patients had no diagnostic findings of RE (RE–). Immunohistochemical staining 
of p53, p16, and Ki-67 was performed on the endoscopic biopsy tissues from the patients with achalasia and 10 control patients with 
non-obstructive dysphagia.
Results: The symptom duration and transit delay were significantly longer in the RE+ group than in the RE– group. We found 
particularly high p53 positivity rates in the RE+ group (p<0.001). The rate of p16 expression was also significantly higher in the RE+ 
group than in the other two groups (p=0.003). 
Conclusions: A high p53 expression rate was more frequently found in the RE+ group than in the other two groups. RE could be a 
meaningful clinical feature of achalasia for predicting esophageal carcinogenesis. Clin Endosc  2018;51:161-166
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INTRODUCTION
Achalasia is a primary esophageal motility disorder of un-
known etiology, characterized by an insufficient relaxation of 
the lower esophageal sphincter and loss of esophageal peristal-
sis.1 The classic symptoms of achalasia consist of dysphagia for 
both solids and liquids, regurgitation of undigested food or 
saliva, respiratory symptoms (nocturnal cough, recurrent as-
piration, and pneumonia), chest pain, and weight loss.2,3 Acha-
lasia is thought to be a premalignant lesion associated with an 
increased risk of esophageal cancer.4 The risk of esophageal 
cancer in patients with achalasia ranges between 10 and 50 
times that in the general population.5-7
Increased bacterial growth and chemical irritation from 
the continuous retention of food and saliva in patients with 
achalasia can induce chronic hyperplastic esophagitis, mu-
cosal dysplasia, and eventually, malignant transformation of 
the esophageal epithelial cells.8 Chronic retention of food and 
saliva leads to esophagitis, which can sometimes be observed 
on endoscopic findings with the presence of mucosal thicken-
ing, nodularity, or cobblestone-like appearance of the mucosa 
and whitish discoloration.8,9 The inflammatory changes found 
in the distal part of the esophagus of patients with achalasia 
are what physicians refer to as retention esophagitis (RE).10,11 
There have been recent increases in the amount of available 
data regarding the morphologic alterations that occur during 
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primary achalasia; these data indicate that alterations in the 
squamous mucosa are uniformly observed.12,13 The inflamma-
tory squamous mucosa associated with end-stage achalasia 
appears significantly altered, including marked squamous hy-
perplasia and increased frequency of p53 immunoreactivity.14 
These changes may be related to an increased risk for esopha-
geal cancer. Although RE in patients with achalasia should be 
considered as a precancerous stage of esophageal cancer, there 
have been few reports regarding endoscopic and histologic 
diagnoses of RE.
Therefore, we aimed to analyze the endoscopic and his-
tologic features of RE in patients with achalasia and clarify 
the clinical meaning of RE as a precancerous lesion based on 
analyses of two tumor suppressor genes, p53 and p16, and a 
proliferation marker, Ki-67.
MATERIALS AND METHODS
Patients and diagnostic examinations
A total of 88 patients with achalasia underwent esophago-
gastroduodenoscopy (EGD) at Gangnam Severance Hospital 
between January 2006 and June 2015. Achalasia was diag-
nosed on the basis of the results of EGD, followed by barium 
esophagography and manometry. Excluding patients who 
underwent previous treatment for achalasia, we retrospectively 
reviewed 37 patients who had undergone histologic exam-
ination at the initial endoscopy. EGD was conducted using 
a high-definition white-light video endoscope (GIFH260Z; 
Olympus medical systems, Tokyo, Japan). Following endo-
scopic observation, the biopsy specimens were obtained within 
5 cm above the esophagogastric junction. Each specimen was 
fixed in 10% formalin and embedded in paraffin wax. 
All endoscopic images of the patients with achalasia were 
reviewed by an experienced endoscopist (HP) who had par-
ticular experience treating esophageal motility diseases. Using 
the Descriptive Rules for Achalasia of the Esophagus that 
were published by the Japan Society of Esophageal Diseases 
in 2012 (Fig. 1), we considered the endoscopic findings of RE, 
i.e., abnormal liquid and/or food retention or thickened and 
whitish changes in the mucosal surface of the esophagus at 
endoscopy.15 Histologic review was performed by two experi-
enced gastrointestinal pathologists. They reviewed the tissues 
from which sufficient specimens were obtained. In all cases, 
hematoxylin and eosin-stained slides were reviewed to con-
firm the diagnosis and to evaluate the presence or absence of 
morphologic alterations in the esophageal squamous mucosa. 
Inflammatory epithelia (esophagitis) were identified by the 
presence of squamous hyperplasia in the mucosal layer (Fig. 2).
We diagnosed RE when both of the following findings were 
present: (1) endoscopically observed food or liquid/foam stasis 
or thickened and whitish color changes in the esophagus mu-
cosa and (2) histologically confirmed esophageal squamous 
hyperplasia. To evaluate retention severity, we classified reten-
tion into the following grades: grade 0 = no retention, grade I 
= foam, grade II = liquid, and grade III = food. 
To serve as controls, we included patients who had under-
gone random esophageal biopsy for the evaluation of non-ob-
structive dysphagia during the study period (January 2006 to 
June 2015). Excluding patients with specific esophagitis (viral, 
reflux, or eosinophilic etc.), 10 patients were evaluated as the 
control group.
This study was approved by the ethics committee of 
Gangnam Severance Hospital, and written informed consent 
was obtained from all subjects.
Immunohistochemistry
Immunohistochemical (IHC) staining was performed on 35 
patients with achalasia (after excluding two empty or inacces-
sible specimens) and 10 control patients. IHC staining for p53 
(sc-126, dilution 1:50; Santa Cruz Biotechnology, Dallas, TX, 
USA), p16 (5A8A4, dilution 1:1,000; Thermo Fisher Scientific, 
Waltham, MA, USA), and Ki-67 (ab15580, dilution 1:1,000; 
Abcam®, Cambridge, UK) was performed using the Novolink 
Polymer Detection System (Leica Biosystems, Richmond, IL, 
USA) according to the manufacturer’s instructions. p53, p16, 
and Ki-67 with immunostaining in ≥15% of cells were con-
sidered positive (Supplementary Fig. 1). The degree of over-
expression was classified as follows: negative, <15%; moderate 
positive, 15%–40%; and strong positive, >40%.16,17
Statistics
The Chi-square and Fisher’s exact tests were used to eval-
uate associations among various categorical variables and 
Student’s t-test, among non-categorical variables. All analyses 
were conducted using SPSS version 20.0 for Windows (SPSS, 
Chicago, IL, USA), and p-value <0.05 was considered statisti-
cally significant. 
RESULTS
Clinical features of the patients
Among the 37 patients with esophageal achalasia in this 
study (male:female sex = 15:22), the mean age at diagnosis 
was 42.0±15.9 years (mean±standard deviation). Twenty-eight 
patients had endoscopic findings of retention in the esopha-
gus; however, seven of these patients did not have squamous 
hyperplasia in the esophagus mucosa. These seven patients 
without squamous hyperplasia were included in the non-RE 
   163 
Kim H et al. Retention Esophagitis in Achalasia
achalasia group. Ultimately, 21 patients had diagnostic find-
ings of RE (RE+), and 16 patients had no diagnostic findings 
of RE (RE–). Table 1 shows the clinical features of all enrolled 
patients with achalasia. The mean symptom duration was 
longer in the RE+ group than in the RE– group (54.9±75.8 
months vs. 39.3±38.7 months, respectively, p=0.008). The 
RE+ group showed food stasis in the esophagus lumen more 
often than did the RE– group. Additionally, the RE+ group 
had significantly longer transit delays on esophageal transit 




There was a significantly greater frequency of p53 immu-
noreactivity in the RE+ group than in the control and the 
RE– groups (Table 2). Further, we also observed significantly 
higher levels of p53 expression (>40%) in the RE+ group than 
in the other two groups (Table 3, Fig. 3). In the post hoc anal-
ysis, the RE+ group vs. control group and RE+ control vs. RE– 
group showed statistical significances (Tables 2, 3). 
p16 expression
p16 expression was available in 33 of the 37 patients with 





Fig. 1. Endoscopic diagnostic findings for retention esophagitis. (A) Liquid/foam stasis with mucosal thickening. (B) Food stasis with mucosal thickening. (C) Mucosal 
thickening. (D) Whitish change with food stasis.
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achalasia samples were excluded owing to inaccessible back-
ground staining. The incidence of positive p16 expression was 
significantly higher in the RE+ group than in the other two 
groups (Table 4). However, the degree of overexpression was 
not statistically significant (data not shown).
Ki-67 expression
Table 5 shows the Ki-67 protein expression profiles for the 
enrolled samples. There was no significant difference in the 
Ki-67 expression among the RE+, RE–, and control groups. 
DISCUSSION
Patients with achalasia have a significantly increased risk of 
developing esophageal cancer.4,18 Achalasia-associated esopha-
geal cancer may arise as a result of chronic food stasis, leading 
to chronic inflammation, epithelial hyperplasia, and multi-fo-
cal dysplasia.18 Although many studies suggest that chronic 
food and saliva stasis in achalasia may lead to esophageal 
cancer, only a few reports have analyzed achalasia-associated 
“retention” esophagitis.9,10,19
Herein, we analyzed the endoscopic and histologic findings Fig. 2. Histologic findings of retention esophagitis (arrow, squamous hyper-
plasia, hematoxylin and eosin stain, ×200).
Table 1. Comparison of Clinical Features between RE+ and RE– Patients
RE+ (n=21) (n, %) RE– (n=16) (n, %) p-value
Age at diagnosis (mean±SD, yr) 42.4±14.2 41.5±18.3 0.872 
Sex (M:F) 1:1.3 1:1.6 0.505 
Main symptom
Dysphagia 10 (47.6) 9 (56.2) 0.825 
Regurgitation 10 (47.6) 6 (37.5)
Chest pain 1 (4.8) 1 (6.2) 
Duration of symptoms (mean±SD, mo) 54.9±75.8 39.3±38.7 0.008 
Grade of retention (n, %)
Grade 0: no retention 0 (0.0)  9 (56.2) <0.001
Grade I: foam 3 (14.3)  4 (25.0)
Grade II: liquid  8 (38.1)  3 (18.8)
Grade III: food 10 (47.6)  0 (0.0)
Eckardt score (mean±SD) 6.7±2.5 5.6±2.3 0.481 
Achalasia typea) (n, %)
I 5 (38.5) 4 (44.4) 0.506
II 7 (53.8) 3 (33.3)
III 1 (7.7) 2 (22.2)
LES pressure in HRM (IRP, mm Hg) 25.3±15.8 19.2±12.5 0.290
ETS R30b) (%) 48.8±21.3 43.2±30.6 0.003
Progression of maligancy 0 (0.0) 0 (0.0) -
RE+, patients had diagnostic findings of retention esophagitis; RE–, patients had no diagnostic findings of retention esophagitis; SD, stan-
dard deviation; LES, lower esophageal sphincter; HRM, high resolution manometry; IRP, integrated relaxation pressure; ETS, esophageal 
transit scintigraphy.
a)Excluded patients failed HRM. 
b)The residual fraction of maximum radioactivity in the distal esophagus after 30 seconds.
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in patients with achalasia according to the presence or ab-
sence of RE. We defined RE on the basis of both endoscopic 
and histologic features, such as abnormal liquid and/or food 
retention in the esophagus or thickening and whitish changes 
in the mucosal surface and histological squamous hyperpla-
sia in the esophageal mucosa. Several previous studies have 
reported that the squamous mucosa from esophagectomy 
specimens that were obtained from patients with end-stage 
achalasia showed evidence of gastroesophageal reflux disease, 
which is characterized by the presence of marked and diffuse 
squamous hyperplasia with papillomatosis and basal cell 
hyperplasia.13,14,20 On the basis of these data, we defined acha-
lasia-associated RE from the histological findings based on 
evidence of squamous hyperplasia in the mucosal layer. These 
inflammatory changes in the esophageal mucosa may be trig-
gered by continuous retention of food and saliva.
We found that patients with achalasia and RE experienced 
significantly longer symptom durations. Furthermore, the 
esophageal mucosal tissues from the RE+ group had higher 
positive rates of p53 and p16 expression than those from the 
RE– and control groups. These results suggest that long-stand-
Table 2. p53 Protein Expression Profiles 
RE+ (n=25) (n, %) RE– (n=10) (n, %) Control (n=10) (n, %) p-value
Negative   5 (20.0) 6 (60.0) 9 (90.0)
Positive 20 (80.0) 4 (40.0) 1 (10.0) <0.001a)
RE+, patients had diagnostic findings of retention esophagitis; RE–, patients had no diagnostic findings of retention esophagitis.
a)RE+ vs. control, p<0.001; RE+ vs. RE–, p=0.031; No statistical significance between other groups.
Table 3. Degree of p53 Protein Expression Positivity
RE+ (n=25) (n, %) RE– (n=10) (n, %) Control (n=10) (n, %) p-value
Negative (<15%)   5 (20.0) 6 (60.0) 9 (90.0)
15%–40% 10 (40.0) 3 (30.0) 1 (10.0) <0.001a)
>40% 10 (40.0) 1 (10.0) 0 (0.0)
RE+, patients had diagnostic findings of retention esophagitis; RE–, patients had no diagnostic findings of retention esophagitis.
a)RE+ vs. control, p<0.001; RE+ vs. RE–, p=0.015; No statistical significance between other groups.
Table 4. p16 Protein Expression Profiles 
RE+ (n=23) (n, %) RE– (n=10) (n, %) Control (n=10) (n, %) p-value
Negative   7 (30.4) 6 (60.0) 9 (90.0)
Positive 16 (69.6) 4 (40.0) 1 (10.0) 0.003a)
RE+, patients had diagnostic findings of retention esophagitis; RE–, patients had no diagnostic findings of retention esophagitis.
a)RE+ vs. control, p=0.002; No statistical significance between other groups.
Table 5. Ki-67 Protein Expression Profiles 
RE+ (n=25) (n, %) RE– (n=10) (n, %) Control (n=10) (n, %) p-value
Negative   7 (28.0) 3 (30.0) 3 (30.0)
Positive 18 (72.0) 7 (70.0) 7 (70.0) 0.989
RE+, patients had diagnostic findings of retention esophagitis; RE–, patients had no diagnostic findings of retention esophagitis.
Fig. 3. Level of p53 expression in retention esophagitis by study group. RE+, 
patients had diagnostic findings of retention esophagitis; RE–, patients had no 
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ing achalasia with RE may be related to an increased risk of 
esophageal cancer. Leeuwenburgh et al.16 reported that overex-
pression of the tumor suppressor gene p53 was a predictor for 
the development of esophageal cancer in patients with acha-
lasia. Additionally, p16 was found to be a key regulator at the 
G1-S checkpoint in the cell cycle, and functional alterations 
in its expression may be important in carcinogenesis.21 Nowa-
days, with the introduction of high-resolution endoscopy and 
chromoendoscopy with Lugol’s staining, the detection sensi-
tivity for premalignant lesions has improved significantly.22 
Therefore, we suggest that patients with RE+ undergo more 
intensive endoscopic surveillance with shorter intervals to de-
tect malignant changes in the esophageal mucosa.
Our study had several limitations. First, we only analyzed 
patients who underwent endoscopic biopsy; thus, we had 
a selection bias. Second, the sample size of each group and 
tissue amount were too small. A large-scale prospective study 
is needed to validate the precancerous risks found to be asso-
ciated with RE in patients with achalasia. Nevertheless, this 
study is the first study to suggest that endoscopic and histo-
logic diagnoses of RE are important for cancer prediction and 
is also the first to clarify the clinical significance of RE as a 
precancerous lesion through IHC staining of biomarkers.
In conclusion, RE could be an important endoscopic and 
histologic feature of achalasia, which may help physicians pre-
dict esophageal cancer risk in patients with achalasia. There-
fore, patients with achalasia and RE should undergo more 
intensive surveillance in shorter intervals to detect malignant 
transformations. 
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